Work in CML suggests that JAK1–3 activation is mediated through the interaction of BCR–ABL1 with cytokine receptors rather than direct phosphorylation (51). The gene discussed is JAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.